Is Yunnan Botanee (Winona) profitable in 2026?

Yes but shrinking. H1 2025 net profit attributable to shareholders fell 49.01% YoY to CNY 246.66 million, from CNY 483.77 million in H1 2024, per the company's semi-annual report filed August 28, 2025. Revenue also fell 15.43% YoY in the same period.

Who is Winona's biggest competitor?

Proya Cosmetics is the main domestic threat, having crossed CNY 10 billion in FY2024 revenue versus Botanee's roughly CNY 5.67 billion, and reportedly outgrew L'Oreal China in a 2023 shopping festival. L'Oreal's CeraVe and La Roche-Posay also compete directly in China's sensitive-skin segment.

Could AI replace Yunnan Botanee or Winona?

No. Yunnan Botanee is a physical skincare manufacturer selling functional products through e-commerce, pharmacy, and dermatology channels; frontier AI has no bearing on its core competitive threat. The real risk is brand and channel share loss to Proya and multinational rivals, not automation.

Is Winona still the leading sensitive-skin skincare brand in China?

Winona has held roughly 15 years of brand recognition and doctor/pharmacy channel presence in China's sensitive-skin segment, but its lead is eroding: H1 2025 revenue fell 15.43% YoY and net profit fell 49.01% YoY, per the company's semi-annual report dated August 28, 2025.

Where does Yunnan Botanee stock trade?

Yunnan Botanee (Botanee, stock name Winona parent) listed on the Shenzhen Stock Exchange ChiNext board on March 25, 2021 under ticker 300957, becoming China's first listed functional-skincare company. It is not listed in Shanghai.

Is Yunnan Botanee expanding outside China?

Yes. The company opened a Southeast Asia headquarters in Bangkok in early 2024 and formally entered the Thailand market in July 2025 via retailers BEAUTRIUM and EVEANDBOY, while also expanding into Hong Kong and Macao Mannings stores, per a July 15, 2025 announcement.

Consumer brands · China

Yunnan Botanee Bio-Technology Co., Ltd. (Winona)

Winona is China's biggest sensitive-skin skincare brand, sold through pharmacies and dermatologists.

Losing its protection

Assessed 26 July 2026 · Evidence as of 26 July 2026

The structural protection is eroding.

On the recordSince 26 July 2026 · Checkable from April 2026 · Every call on the record Checkpoint: FY2025 full-year revenue and profit results

The call

Botanee still owns the sensitive-skin shelf in Chinese pharmacies, but Proya and L'Oréal are pulling customers away while its own numbers fall.

Winona makes skincare products for sensitive skin and built a strong brand position in China over 15 years, selling mainly through doctors and pharmacies at high profit margins. But being well-known is not enough to stop copycats: L'Oréal's CeraVe and La Roche-Posay brands, plus the domestic company Proya, are actively stealing customers and offer similar products. The company's sales fell 15 percent in the first half of 2025 and profits fell nearly 50 percent, showing the threat is real and happening now, not just a future worry. What matters next is whether Winona can stabilize its core business or if the decline keeps accelerating through the rest of 2025 and into 2026, because if the bleeding continues at this pace, the brand may become too weak to compete.

Why

AI pressure: None apparent. AI skincare-diagnosis apps and personalization tools exist in the category but aren't cited as a factor in Botanee's decline. Could AI do the core job? Unlikely.

Bigger players: L'Oréal China (CeraVe, La Roche-Posay) and domestic rival Proya. Proya now runs about twice Botanee's revenue and reportedly outsold L'Oréal in recent shopping festivals, while Botanee's own sales shrink. Could a giant copy it? Yes, easily.

What protects it. A 15-year run as the top sensitive-skin brand in China's pharmacy and dermatologist channel, with 75% gross margins still intact.

What would change this call

Botanee's FY2025 full-year revenue and net profit report, expected around April 2026. Shows whether the H1 2025 decline was a one-off dip or an ongoing loss of share to rivals.
Proya's and CeraVe's sales rankings in the dermocosmetics category during Double 11 and 618 shopping festivals. Indicates whether these rivals are converting Winona's specific customer base or just growing the overall category.
AOXMED brand revenue disclosure in Botanee's next annual or semi-annual report. Tests whether the clinic/dermatologist channel strategy is scaling past a rounding error or remains defensive.

Key numbers

H1 2025 revenue fell 15.4% YoY to CNY 2.37B (2025-08-28)
H1 2025 net profit fell 49% YoY to CNY 247M (2025-08-28)
AOXMED device brand made just CNY 59.9M in FY2024 (2025-04-25)

Named risks

H1 2025 revenue fell 15.43% YoY, signaling core brand demand is actively shrinking. Severity: high
H1 2025 net profit fell 49.01% YoY, well outpacing the revenue decline. Severity: high
Diversification brand AOXMED generated only CNY59.92 million in FY2024 versus a roughly CNY5.5 billion core business. Severity: medium
Proya and multinational brands like CeraVe and La Roche-Posay are actively taking share in the exact sensitive-skin/derma positioning Winona occupies. Severity: medium
No structural or regulatory barrier prevents rivals from entering Winona's pharmacy/dermatologist channel. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Proya Cosmetics	gaining on	Proya crossed CNY10B FY2024 revenue vs Botanee's ~CNY5.67B, roughly double, as of 2024
L'Oreal China (CeraVe, La Roche-Posay)	contesting	Proya outgrew L'Oreal China in 618 festival GMV in 2023, showing multinational share is contestable too
Shiseido China	contesting	Direct multinational competitor in premium derma-skincare segment as of 2025
Kose China	contesting	Multinational incumbent occupying adjacent premium sensitive-skin positioning as of 2025
Shanghai Jahwa	contesting	Domestic peer fell 13.9% FY2024 revenue with CNY833M net loss, showing sector-wide pressure

Questions people ask

Is Yunnan Botanee (Winona) profitable in 2026?: Yes but shrinking. H1 2025 net profit attributable to shareholders fell 49.01% YoY to CNY 246.66 million, from CNY 483.77 million in H1 2024, per the company's semi-annual report filed August 28, 2025. Revenue also fell 15.43% YoY in the same period.
Who is Winona's biggest competitor?: Proya Cosmetics is the main domestic threat, having crossed CNY 10 billion in FY2024 revenue versus Botanee's roughly CNY 5.67 billion, and reportedly outgrew L'Oreal China in a 2023 shopping festival. L'Oreal's CeraVe and La Roche-Posay also compete directly in China's sensitive-skin segment.
Could AI replace Yunnan Botanee or Winona?: No. Yunnan Botanee is a physical skincare manufacturer selling functional products through e-commerce, pharmacy, and dermatology channels; frontier AI has no bearing on its core competitive threat. The real risk is brand and channel share loss to Proya and multinational rivals, not automation.
Is Winona still the leading sensitive-skin skincare brand in China?: Winona has held roughly 15 years of brand recognition and doctor/pharmacy channel presence in China's sensitive-skin segment, but its lead is eroding: H1 2025 revenue fell 15.43% YoY and net profit fell 49.01% YoY, per the company's semi-annual report dated August 28, 2025.
Where does Yunnan Botanee stock trade?: Yunnan Botanee (Botanee, stock name Winona parent) listed on the Shenzhen Stock Exchange ChiNext board on March 25, 2021 under ticker 300957, becoming China's first listed functional-skincare company. It is not listed in Shanghai.
Is Yunnan Botanee expanding outside China?: Yes. The company opened a Southeast Asia headquarters in Bangkok in early 2024 and formally entered the Thailand market in July 2025 via retailers BEAUTRIUM and EVEANDBOY, while also expanding into Hong Kong and Macao Mannings stores, per a July 15, 2025 announcement.

Timeline

2026-04-27FY2025 annual report summary filed, describing further Winona brand repositioning
2025-08-28H1 2025 revenue down 15.43% YoY, net profit down 49.01% YoY per semi-annual filing
2025-07-15Formal Thailand market entry and Hong Kong/Macao Mannings expansion announced
2025-04-25FY2024 annual report shows AOXMED sales of CNY 59.92 million, Winona 2.0 relaunch confirmed
2024-10-25Q1-Q3 2024 revenue up 5.98% YoY but net profit down 28.39% YoY
2024-01Southeast Asia headquarters opened in Bangkok
2023-06-02Proya reportedly surpassed L'Oreal China in 618 shopping festival growth
2021-03-25Listed on Shenzhen Stock Exchange ChiNext board, ticker 300957
2010-05-13Company founded in Kunming as Kunming Botanee Biotechnology Co., Ltd.

Revision history

26 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

PVH VF Kering